Abstract: Chronic renal failure (CRF) is a complex clinical entity caused by progressive destruction of functional renal parenchyma in the course of various pathological processes resulting in complete failure of renal function and subsequent metabolic, acid base and electrolyte as well as immune disorders. Renal transplantation (RT) is one of the renal replacement therapy options in the terminal stage of chronic renal failure. The replacement of the failing organ with one from a healthy donor may be complicated with immune host response. This study was designed to investigate the changes in serum concentration of integrins CD11a/CD18, CD11b/CD18, CD69 on the surface of human polymorphonuclear leukocytes (PMNL) after the RT within two six-month periods. The study included 25 RT patients (mean 5.4±2.7 yrs after the transplantation, 10 females and 15 males) treated with immune suppressive therapy including cyclosporine A, azathioprine and prednisolone. The expression was assessed with monoclonal antibodies by means of flow cytometry. Also, the expression of CD69 was determined before and after phytohemaglutinine (PHA) stimulation. There was no significant alternation in serum concentration of CD11a/CD18, CD11b/CD18 and CD69 at baseline, six months and twelve months later. The expression of integrins was not altered in renal transplantation patients in the current study setting.
Introduction
Chronic renal failure (CRF) is a complex clinical entity caused by progressive destruction of functional renal parenchyma in the course of various pathological processes resulting in complete failure of renal function and subsequent metabolic, acid base and electrolyte as well as immune disorders [1] . Renal transplantation (RT) is one of the renal replacement therapy options in the terminal stage of CRF. The replacement of the failing organ with a healthy donor one may be complicated with immune host response leading to rejection of the transplanted organ. The immune tolerance cannot be induced despite the remarkable progress in the knowledge of immune mechanisms involved in host versus graft reaction. Consequently, renal transplantation evokes immune response eventually leading to the graft rejection. The host versus graft reaction includes the inducing and effector phases. The inducing phase involves antigen presentation, recognition and the proliferation of antigen specific host lymphocytes. The inducing phase is indirect via graft MHC antigen presentation to host lymphocytes T by antigen presenting cells (APC) and direct via graft antigen presentation on the surface of host APC to graft lymphocytes T [1, 6] . The antigen presentation is mediated by T cell receptors. The response of lymphocytes T helpers to antigens is supported with co-receptors, by their increased adhesion with APC, and the signals accelerate the initial activation cascade. The effector phase involves specific immune reactions. After the recognition macrophages release IL-1 leading to the proliferation of T helper cells, the activated T helper cells release IL-2, which brings about the proliferation of cytotoxic lymphocytes. The activated lymphocytes T produce interferon γ and other chemotactic factors. T helpers not only activate cytotoxic lymphocytes T but also may initiate delayed hypersensitivity. During that phase, non-specific, cytokine-mediated activation of polymorphonuclear leukocytes and macrophages occurs. This reaction is mediated by cell surface integrins, adhesins and selectins. Some of these proteins are integral cell surface antigens and mediate intercellular communication and reactions with the extracellular matrix [1, 3] .
Immune disorders in RT are associated with complex alternations in immunocompetent cell reactivity, the phenotype changes of cell surface receptors, and disordered equilibrium of immune mediators responsible for the regulation of fine immune mechanisms. The immune disorders originate from both impaired renal filtration with subsequent metabolic CRF and uremic toxin accumulation as well as the immune host reaction to the graft tissue [2] . The transplantation, in general, mobilizes immune response involving recognition and the active damage to the graft organs. It is executed in the course of active immune reaction with immune competent cells playing an active role.
The integrins CD11a/CD18 and CD11b/CD18, expressed on the surface of human lymphocytes, monocytes, polymorphonuclear leukocytes (PMNL), are capable of binding intercellular adhesion molecules ICAM-1, ICAM-2 and ICAM-3 expressed on the numerous inflammatory cells and endothelial cells. The expression of another surface antigen CD69 is induced early in stimulated lymphocytes. The elucidation of immune mechanisms of host versus graft reaction is crucial for the preservation of renal function in RT. There is numerous research evidence of their particular involvement in inflammatory cell adhesion and migration [3] [4] [5] .
This study was designed to investigate the alternation of CD11a/CD18, CD11b/CD18 and CD69 expression in six-month intervals in RT patients.
Statistical methods and Experimental Procedures

Study patients
The study included 25 renal transplantation patients (mean 5.4±2.7 yrs after the transplantation, 10 females and 15 males) treated with immune suppressive combination therapy with cyclosporine A (dose of 100-225 mg daily), azathioprine (50-100 mg) and prednisolone (5-10 mg).
Flow cytometry studies
The venous blood samples were obtained from the antecubital vein on a fasting basis. The blood samples assays were performed three times within six-month periods. The expression was assessed with monoclonal antibodies (DAKO) by means of flow cytometry (FACStar flow cytometer, Becton-Dickinson). The antibody reactions with target cell integrins were performed in whole blood samples according to the manufacturer's guidelines. The expression of CD69 was determined before and after PHA stimulation involving 24-hour incubation with phytohemaglutinine (PHA) at the concentration of 10 μg/ml.
Statistical analysis
The results were analyzed with the Mann-Whitney test and expressed the mean fluorescence intensity (MFI). The differences were considered significant at p<0.05.
Results
During the study's initial follow-up period of six months, there was a tendency towards decreased expression of CD11a/CD18 PMNL in comparison with the baseline levels; these alternations were not, however, significant. After another six-month period, this expression was also insignificantly increased. The expression of CD11b/CD18 was increased at the baseline; the statistical analysis in this case also demonstrated that the differences were insignificant.
The expression of CD69 and CD69 expression after 24-hour phytohemaglutinine (PHA) stimulation (CD69/PHA) tended to decrease in the assays after six months and then appeared to increase after another six months, but in each case the differences were not significant (Table 1) .
Discussion
Integrins, as cell surface glycoproteins, participate in cellular aggregation, extracellular matrix interactions, the migration processes, cellular antigen recognition and their segre- gation and the control of cellular morphology. The release of IL-1β, IL-6 and TNFα by integrin-mediated activation stimulates other inflammatory processes, including lymphocytes, and leads to the synthesis of specific cytokines such as IL-2 [7, 8] .
Integrins CD11a/CD18 and CD11b/CD18 are main adhesive receptors, mediating cellular interactions with the extracellular matrix and taking part in intercellular communications and signaling. After ligand-binding, their activation leads downstream to increased phosphorylation, increased Ca 2+ concentration and lowered intracellular pH, phosphoinositol turnover and eventually altered cell functionality with respect to adhesion, aggregation, secretion and proliferation. The final biological effects of inter-and intracellular signaling engaging integrins are diverse and depend on the cell type and ligand type. The majority of immune reactions are shaped by intercellular interactions, with cytokine signaling, modulatory factors, surface receptors of immunocompetent cells and adhesins serving crucial roles. The current study revealed fixed temporal patterns of integrins CD11a/CD18, CD11b/ CD18 and CD69 expression even if the previous reports state otherwise [9] . These discrepancies might hypothetically be related with some patients failing to complete the former study as in some cases, the rejection reaction occurred and the increased expression of inflammatory adhesive proteins might have been related with the initial stage of graft rejection. Other reports found increased expression of graft kidneys when compared with chronic renal failure before transplantation [10] [11] [12] . Schwarz et al. found increased expression of adhesive antigens early in the course of graft rejection [12] [13] [14] [15] [16] . The hereby-reported results might therefore be associated with appropriate immune suppression medication doses and overall good tolerance of grafted tissue.
Although the particular mechanisms of cellular disorders responsible for the immune dysfunction in renal transplantation patients remain to be elucidated, data from the present study combined with available data may demonstrate that the expression of adhesion molecules reflects the chronic inflammatory process that underlies graft rejection.
